RKT

Reckitt Benckiser Group PLC

Personal Care, Drug and Grocery Stores First-pass screen £30.0bn

370/1000 Overall fit

AI beneficiary 35% 15

Operating leverage 25% 62

Valuation 25% 30

Downside protection 15% 58

First-pass take

Reckitt is a defensive consumer staples company with strong brands (Lysol, Dettol, Durex) and 140bps operating margin expansion in 2024. However, it shows zero AI exposure, negative underlying volume growth (-0.6% LFL), and faces material headwinds including a £696m IFCN impairment with no headroom, NEC litigation risks, and 1.4% revenue growth despite pricing power. Returning £2.7bn to shareholders against £2.2bn FCF is unsustainable without growth acceleration.

Flags

no-ai-exposurenegative-volumesnec-litigationimpairmentsno-valuation-data